AMA applauds FDA for approving naloxone product to prevent overdoses

| 2 Min Read

“The American Medical Association (AMA) applauds the Food and Drug Administration (FDA) for approving the nasal spray version of naloxone, a life-saving medication that can reverse the effects of an opioid overdose by restoring breathing and preventing death. The FDA’s swift action will widely increase accessibility to this medication that will help prevent more opioid-related overdoses and save more lives.

“The AMA has long advocated in support of a multi-pronged approach to addressing prescription drug abuse and diversion, which includes increasing access to naloxone for patients who need it.

Full press statement available when you sign in

Sign in to the AMA website to get the full version of this press statement. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Magnifying glass

Making payers’ prior authorization data easier to access, understand

| 4 Min Read
Patient smiles at healthcare worker

Building a strong primary care physician workforce

| 7 Min Read
Row of figures with one called out by an exclamation point

Physician-lawyer on private practice HR: Here’s how to hire—and fire

| 5 Min Read
Mohamad Mokadem, MD, featured on "Health vs. Hype" AMA podcast

9 things that patients should know about gut health

| 5 Min Read